acetylcysteine has been researched along with zithromax in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Navashin, SM; Nikitin, AV | 1 |
| Ahrens, P; Buehring, I; Friedrich, B; Schaaf, J; Schmidt, H; Zielen, S | 1 |
| Hussain, S; Roomans, GM; Särndahl, E; Varelogianni, G | 1 |
| Babić, I; Baudoin, T; Bedeković, V; Trotić, R | 1 |
| Bellon, H; Heigl, T; Hoet, P; Lammertyn, E; Mathyssen, C; Pilette, C; Sacreas, A; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Vriens, H | 1 |
| Bakshi, SS | 1 |
| Elgaher, WAM; Haupenthal, J; Hirsch, AKH; Lababidi, N; Ofosu Kissi, E; Rades, T; Schneider, M; Schwarz, BC; Sigal, V | 1 |
| Wu, J | 1 |
| de Souza Carvalho-Wodarz, C; Lababidi, N; Lehr, CM; Montefusco-Pereira, CV; Schneider, M | 1 |
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
| Björnsson, ES | 1 |
3 review(s) available for acetylcysteine and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Tackle the free radicals damage in COVID-19.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Azithromycin; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Therapy, Combination; Free Radicals; Glutathione; Humans; Hydroxychloroquine; Mice; Multiple Organ Failure; NF-E2-Related Factor 2; Nitric Oxide; Orthomyxoviridae Infections; Oxidative Stress; Pandemics; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Clinical management of patients with drug-induced liver injury (DILI).
Topics: Acetylcysteine; Aged; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Azithromycin; Checklist; Chemical and Drug Induced Liver Injury; Female; Humans; Jaundice; Middle Aged; Pruritus; Symptom Assessment | 2021 |
2 trial(s) available for acetylcysteine and zithromax
| Article | Year |
|---|---|
Chronic sinusitis refractory to standard management in patients with humoral immunodeficiencies.
Topics: Acetylcysteine; Administration, Intranasal; Adolescent; Adult; Agammaglobulinemia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Ataxia Telangiectasia; Azithromycin; Beclomethasone; Blood Proteins; Child; Child, Preschool; Chronic Disease; Common Variable Immunodeficiency; Eosinophil Granule Proteins; Ethmoid Sinusitis; Female; Frontal Sinusitis; Glucocorticoids; Humans; Immunization, Passive; Interleukin-8; Lymphoproliferative Disorders; Magnetic Resonance Imaging; Male; Nasal Lavage Fluid; Paranasal Sinuses; Radiography; Ribonucleases; Sinusitis; Tumor Necrosis Factor-alpha | 1997 |
Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion.
Topics: Acetylcysteine; Acoustic Impedance Tests; Anti-Bacterial Agents; Azithromycin; Child; Child, Preschool; Drug Therapy, Combination; Expectorants; Female; Humans; Male; Otitis Media with Effusion; Prospective Studies | 2017 |
13 other study(ies) available for acetylcysteine and zithromax
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
[New macrolide antibiotics, rifamycins and peptide antibiotics discussed at the 27th International Conference on Antimicrobial Agents and Chemotherapy].
Topics: Acetylcysteine; Anti-Bacterial Agents; Azithromycin; Bacterial Infections; Congresses as Topic; Daptomycin; Disaccharides; Drug Evaluation; Erythromycin; Glycopeptides; Humans; New York City; Peptides; Rifamycins | 1991 |
N-acetylcysteine and azithromycin affect the innate immune response in cystic fibrosis bronchial epithelial cells in vitro.
Topics: Acetylcysteine; Azithromycin; Bronchi; Cell Line; Cystic Fibrosis; Epithelial Cells; Humans; Immunity, Innate; Interleukin-6; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Up-Regulation | 2015 |
Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options.
Topics: Acetates; Acetylcysteine; Aminopyridines; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Benzamides; Bronchi; Cell Line; Cyclopropanes; Dapsone; Dexamethasone; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Interleukin-1alpha; Interleukin-8; MAP Kinase Signaling System; Moxifloxacin; Neutrophils; Phosphorylation; Pyridones; Quinolines; Sulfides; Theophylline; Treatment Outcome | 2017 |
In reference to 'Therapeutic efficacy of azithromycin and acetylcysteine in chronic otitis media with effusion'.
Topics: Acetylcysteine; Anti-Bacterial Agents; Azithromycin; Humans; Otitis Media; Otitis Media with Effusion | 2018 |
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
Topics: Acetylcysteine; Administration, Inhalation; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Ciprofloxacin; Cystic Fibrosis; Drug Stability; Drug Storage; Expectorants; Horses; Mucus; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2019 |
Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles.
Topics: Acetylcysteine; Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azithromycin; Ciprofloxacin; Curcumin; Cytokines; Drug Carriers; Drug Combinations; Drug Compounding; Expectorants; Freeze Drying; Humans; Inflammation Mediators; Macrophages; Microbial Viability; Mucus; Nanoparticles; Permeability; Polylactic Acid-Polyglycolic Acid Copolymer; Pseudomonas aeruginosa; Pseudomonas Infections; THP-1 Cells; Tobramycin | 2020 |
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |